Khem Chand

Khem Chand

Active Director Director DIN 07283272
DIN 07283272 First appointment Nov 2015 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2015
Shareholding value •••• Premium profile

About Khem Chand

Data last updated:

Khem Chand is a Director at Unicell Pharma Private Limited (since 2015). The company operates in Pharma. Unicell Pharma Private Limited reported revenue of ₹1.45 Cr (FY 2025).

DIN 07283272
Primary Designation Director
Industry Pharma
First Appointment 13 Nov 2015
Oldest Company Age 11 yrs
Largest company Unicell Pharma Private Limited · ₹1.45 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Unicell Pharma Private Limited U24119PB2015PTC039897
Director13 Nov 20152015₹1.45 Cr (FY 2025)Active

Board colleagues of Khem Chand

NameDINCompanyDesignation
Sandip Kumar07283315Unicell Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Unicell Pharma Private Limited
Premium access

Shareholding and investment profile for Khem Chand

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Khem Chand

Khem Chand currently holds 1 directorship: Unicell Pharma Private Limited (Director, since 13 Nov 2015, revenue ₹1.45 Cr (FY 2025)).

Khem Chand was first appointed on 13 Nov 2015 as Director at Unicell Pharma Private Limited.

The current boards of Khem Chand's companies include Sandip Kumar (Unicell Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available